Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) reported Q2 2017 earnings this Morning, coming in at ($3.46) per share, beating Wall Street’s estimates of ($3.61) per Share. Revenue for the quarter came in at $30.89 million beating analyst estimates of $27.50 million

Analyst Coverage For Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
These are 2 Sell Ratings, 4 Hold Ratings, 10 Buy Ratings .
The current consensus rating for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is Buy (Score: 2.50) with a consensus target price of $203.00 , a potential (50.34% upside)

Recent Insider Trading for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

• On 7/20/2017 Daniel G Welch, Director, sold 217 with an average share price of $126.76 per share and the total transaction amounting to $27,506.92.
• On 7/14/2017 Richard J Kim, SVP, sold 89 with an average share price of $128.64 per share and the total transaction amounting to $11,448.96.
• On 7/11/2017 David Shapiro, CMO, sold 553 with an average share price of $124.01 per share and the total transaction amounting to $68,577.53.
• On 7/3/2017 David Shapiro, CMO, sold 350 with an average share price of $121.24 per share and the total transaction amounting to $42,434.00.
• On 7/3/2017 Lisa Bright, Insider, sold 394 with an average share price of $121.33 per share and the total transaction amounting to $47,804.02.
• On 7/3/2017 Mark Pruzanski, CEO, sold 1,434 with an average share price of $121.78 per share and the total transaction amounting to $174,632.52.

Recent Trading for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
Shares of Intercept Pharmaceuticals, Inc. closed the previous trading session at 123.12 down -11.91 -8.82% with 755,345 shares trading hands.